Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Obatoclax is a pan-Bcl-2 inhibitor with promising efficacy, especially when combined with other antineoplastic agents. Pharmacokinetic drug-drug interactions can occur systemically and at the level of the tumour cell. Thus, this study scrutinised the interaction potential of obatoclax in vitro.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Pharm. Pharmacol.

Title: The Journal of pharmacy and pharmacology

Publisher: Wiley

ISSN (Electronic): 2042-7158

ISSN (Print): 0022-3573

Publication date (Electronic): Nov 2015

Volume: 67

Issue: 11

Affiliations

[1 ] Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.

[2 ] National Centre for Tumour Diseases, Department of Medical Oncology, Internal Medicine VI, University of Heidelberg, Heidelberg, Germany.

Article

DOI: 10.1111/jphp.12455

PubMed ID: 26255619

SO-VID: 0fb4e47b-651d-43ed-b1b9-642122181f89

History

Keywords: drug transporters,drug-drug interaction,obatoclax,CYPs

Data availability:

Keywords: drug transporters, drug-drug interaction, obatoclax, CYPs

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.